S3 of lung cancer cases and deaths were obtained from the Global Burden of Disease Study. RESULTS: The total SAE of lung cancer was estimated as US $9527.1 million in China in 2015 (accounting for 0.09% of the local gross domestic product), the decomposed direct and indirect SAE were estimated as $2505.0 million (accounting for 0.4% of total healthcare expenditure in local) and $7022.1 million (73.7% of total SAE), respectively. With 42.0% and 2.4% smoking prevalence among male and female in 2005, 93.5% of the total SAE occurred in male lung cancer in 2015 ($8903.3 million). Mainly due to the variation of burden of disease, age-specific total SAE peaked at 60-64 years group, urban areas' total SAE higher than rural areas'. In 2025, the SAE of lung cancer, compared with that in 2015, would increase by 30.9% ($12471.0 million). CONCLUSIONS: This might be the most detailed estimation on economic burden of lung cancer attributable to smoking in China. SAE caused by lung cancer accounted at least one tenth of all-diseases-caused SAE, compared to previous study. Without main population-level smoking intervention introduced, the economic burden of lung cancer attributable to smoking will continually increase over the next ten years.
This study aimed to systematically review cost-effectiveness data of trastuzumab as an adjuvant treatment for early breast cancer in Asia. METHODS: Literature search, which ended on February 2018, was performed using five electronic databases (i.e. PubMed, SCOPUS, COCHRANE, CRD and Web of Science). Studies were identified by two independent reviewers in accordance to inclusion and exclusion criteria. References of the included studies were also screened for other relevant reports, with restriction to English language. Relevant data were extracted and assessed for risk of bias. The quality of each study was assessed using the checklist proposed by the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement, Drummond and Philips checklists. To compare different currencies that have been used in the studies, all costs were converted to US dollars (US$) 2018. RESULTS: Six out of 250 studies identified met the inclusion criteria. Five were cost-effectiveness analysis (CEA) and one was cost-benefit analysis (CBA). The majority of the economic analyses were performed from the healthcare provider perspective. All CEA, except one Iranian study, obtained effectiveness data from HERA trial. For the quality assessment, all studies fulfilled more than 50% of the requirements in the CHEERS, Drummond and Phillips checklists. The incremental cost-effectiveness ratio (ICER) for evaluations performed for a time horizon of 20 years was US$51,863/QALY while studies that applied lifetime horizon reported an ICER of between US$7,676 /QALY to 22,664.75 /QALY. The model outcome was generally sensitive to changes in cost of trastuzumab, discount rate and duration of trastuzumab. CONCLUSIONS: One-year treatment of adjuvant trastuzumab for patients with early breast cancer in the Asian countries was found to be cost-effective.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.